🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very interesting #ASCO23 abstract. If a patient w/ cancer has HIV, they miss out on 50% of active clinical trials! 🤯 meetings.asco.org/abstracts-pres… Worst part? No reason for exclusion in most cases…. More work to do.. Amin Nassar, MD Rafeh Naqash, MD Guru P. Sonpavde, MD Kate Lurain David James Pinato 🇺🇦

I met a person with HIV (PWH) and Kaposi sarcoma this week who was denied cancer care by local oncologists. We look forward to taking over their cancer care on our trial. When is exclusion no longer going to be an issue for PWH and cancer? At #ASCO 2023 meetings.asco.org/abstracts-pres…

Very heartwarming to see that our research was very welcomed by the #MedTwitter community! Toni Choueiri, MD Guru P. Sonpavde, MD Kate Lurain Ramya Ramaswami Elad Sharon Nazli Dizman Brinda Emu Tarek Haykal, MD, MHS IMG Oncologists Dana-Farber Lank Center for Genitourinary Oncology Yale Internal Medicine #CATCHIT

Particularly enjoyed this plenary session as people with HIV (PWH) were included and enrolled. Important that this was done with increasing incidence of Hodgkin lymphoma in PWH #HIVOnc

Best part about conferences is catching up with, and seeing friends do great things. Jennifer Crombie, MD Kate Lurain #ASCO23

Very timely Oncology Grand Rounds Journal of Clinical Oncology on HIV/ICI. Here, Kate Lurain elegantly summarizes the literature w/ informative recommendations for clinical practice and presents a case of a person living with HIV + Hodgkin Lymphoma who had a complete response to Pembrolizumab.

Incidence of Burkitt lymphoma in the United States during 2000 to 2019 - PubMed: BL rates are multimodal- biological heterogeneity?; rates rose and fell-diagnostic or etiological factors? Survival improved by 20% points, but still low in black individuals. pubmed.ncbi.nlm.nih.gov/37278097/

Last in-person Friday didactics of the 2022-23 cycle, celebrating our ultra-dedicated chief Krithika Shanmugasundaram and her incoming🤰🏽👶 with a multi-national potluck 🇮🇳🇨🇲🇧🇷🇨🇦🇵🇰🇺🇸🇩🇪🇰🇷 🇮🇪 Hem-Onc Fellows Network life @NCICCR_MOS

Excited to share our publication showing that personalized behavioral interventions improve engagement in care for people living with HIV #hivonc Grateful for the opportunity to work with amazing colleagues Elvin Geng Maya Petersen Eliud Akama Harriet Fridah Kenya Medical Research Institute

Also such a wonderful group of caring and compassionate clinical researchers! Congrats on your achievements Kate Lurain and Ramya Ramaswami 👏🏻

Excited to see the important results of BV-AVD in HIV+ Hodgkin lymphoma in print! 2-yr PFS 87% and OS 92% plus increases CD4/CD8 counts. Great work by Paul Rubinstein and AMC Operations sciencedirect.com/science/articl…

I'm excited to share that our new paper is published. Many thanks to our wonderful team that made this possible. We are also grateful to the clinical trial participants for their contributions. #kshv #hhv8 #RNAseq #herpes #virus #OpenAccess doi.org/10.1186/s12967…

Congratulations to our inspirational #LEAD2023 Rising Star Jaydira Del Rivero, MD Women Leaders in Oncology

Congrats to my dear friend and amazing clinician-scientist Ramya Ramaswami We couldn’t be luckier to have her brilliant research and compassionate care for our patients in the HIV and AIDS Malignancy Branch @NCIResearchCtr

Wish I were @ASH to see Kate Lurain et al's important rb.gy/5f7c6d on CATCH-IT RWE for anti-PD1 in #HIV #Hodgkin #lymphoma today. Encouraging activity after med 2nd line Tx in EBV+ disease (unique biology in HIV ): 70% CR rate, 20 mo DOR including in low CD4!

The future of oncology is bright! Inspiring to meet with superstar fellow Houssein Safa, MD at #ASCO24

Hot off the press from Kate Lurain Ramya Ramaswami TAO Elad Sharon Denise Whitby Important new data showing high and durable activity for anti-PD1 in HIV-KS! CITN12: Pembro in HIV-Associated Kaposi Sarcoma | JCO ascopubs.org/doi/10.1200/JC…

IO can be safe and effective for HIV-KS. CITN12: Pembrolizumab in HIV-Associated Kaposi Sarcoma | ⁦Journal of Clinical Oncology⁩ ⁦Kate Lurain⁩ ⁦Elad Sharon⁩ ⁦Thomas Uldrick, MD⁩ ascopubs.org/doi/10.1200/JC…

New research from TAO and team highlights the promise of immunotherapy for HIV-associated Kaposi sarcoma in treating KS in people living with HIV. #CancerResearch #HIV #Immunotherapy #KaposiSarcoma Read More: ascopubs.org/doi/10.1200/JC…